Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the ...

Researchers sought to determine whether adding elotuzumab to PVd would be safe and effective in treating patients with relapsed or refractory MM.

The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

Glenmark Pharmaceuticals Ltd.'s subsidiary, IGI, is set to be listed in the US in the coming year, according to Chairman and Managing Director Glenn Saldanha. Speaking about the mega deal with AbbVie, ...

AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), have ...

Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer ...

IGI Therapeutics has signed an exclusive licensing agreement with AbbVie, for ISB 2001 to treat cancer and autoimmune diseases.

AbbVie partners with Ichnos Glenmark to develop ISB 2001, a trispecific antibody for multiple myeloma, in a $1.9B licensing ...

Teclistamab shows promising results in high-risk multiple myeloma patients, including those ineligible for trials due to ...

Glenmark Pharmaceuticals hit an upper limit of 10% to a record high of Rs 2095.65 after its subsidiary Ichnos Glenmark Innovation (IGI) unveiled a global commercialization strategy for its lead ...